Key terms

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest GILD news

Apr 08 10:50pm ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO) by TipRanks Apr 08 3:18pm ET Fly Insider: Xilio, Aerovate among week’s notable insider trades by TipRanks Apr 02 7:12am ET Nurix Therapeutics announces extension of collaboration with Gilead by TipRanks Mar 28 8:49am ET Gilead announces FDA approval for Vemlidy sNDA by TipRanks Mar 28 7:22am ET Gilead sees FY24 EPS reduction of 3c-4c from Xilio Therapeutics deal by TipRanks Mar 28 7:13am ET Xilio Therapeutics, Gilead announce exclusive license agreement for XTX301 by TipRanks Mar 28 7:10am ET Xilio to get $43.5M upfront in pact with Gilead to develop/commercialize XTX301 by TipRanks Mar 24 5:03am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD) by TipRanks Mar 22 9:41am ET Unusually active option classes on open March 22nd by TipRanks Mar 22 9:32am ET Gilead Sciences Bolsters Portfolio with CymaBay Acquisition by TipRanks Mar 22 9:27am ET Gilead completes acquisition of CymaBay by TipRanks Mar 22 9:27am ET Gilead says CymaBay deal to lower 2024 EPS by $3.35-$3.45 by TipRanks Mar 19 4:34pm ET Gilead to contact other potential bidders in light of recent media reports by TipRanks Mar 19 2:00am ET Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Gilead Sciences (GILD) by TipRanks Mar 15 12:03pm ET JPMorgan biotech/pharma analysts hold an analyst/industry conference call by TipRanks Mar 14 4:25pm ET Kevin Lofton Retires from Gilead Sciences Board by TipRanks Mar 13 6:50am ET Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY) by TipRanks Mar 11 8:41am ET Gilead announces expiration of HSR waiting period for CymbaBay tender offer by TipRanks Mar 11 7:01am ET Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Crinetics Pharmaceuticals (CRNX) by TipRanks Mar 08 7:47am ET Merus price target raised to $52 from $44 at BofA by TipRanks Mar 06 4:32pm ET Gilead says Biktarvy demonstrates high rates of viral suppression by TipRanks Mar 06 10:28am ET Gilead, Merck announce Phase 2 data on islatravir-lenacapavir combination by TipRanks Mar 06 8:15am ET Merus to potentially receive $56M in deal with Gilead to discover antigens by TipRanks Mar 06 8:12am ET Gilead receives option to license novel trispecific therapeutics in Merus deal by TipRanks Mar 06 8:10am ET Merus to receive $56M upfront in deal with Gilead to discover antigens by TipRanks Mar 05 4:38pm ET Gilead says new data further support use of Veklury in Covid-19 hospitalizations by TipRanks Mar 05 8:59am ET Arcellx price target raised to $87 from $57 at Truist by TipRanks Mar 05 8:59am ET Arcellx price target raised to $87 from $57 at Truist by TipRanks Mar 04 11:57am ET Gilead price target lowered to $78 from $84 at Wells Fargo by TipRanks Feb 29 7:52am ET Arcellx price target raised to $77 from $65 at BofA by TipRanks Feb 29 7:26am ET Abingworth announces financing agreement with Gilead by TipRanks
Yesterday 9:00am ET Better Growth Play: Merck or The Vanguard Growth Index Fund? by Motley Fool Yesterday 8:00am ET Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq? by Motley Fool Apr 06 6:49am ET 3 No-Brainer Dividend Stocks to Buy in April by Motley Fool Apr 05 8:30am ET Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows by Motley Fool Mar 17 8:15am ET 2 Top Dividend Stocks to Buy Hand Over Fist by Motley Fool Mar 10 6:35am ET 3 Dividend Stocks to Buy Hand Over Fist in March by Motley Fool Mar 09 9:00am ET The AI Race Gets Litigious by Motley Fool
Apr 02 9:15am ET Gilead Sciences Champions Equal Pay by Accesswire Mar 26 9:15am ET Winn Awards Help Physicians Solve Healthcare Disparities by Accesswire Mar 19 9:05am ET Gilead Helps Launch Türkiye’s First HIV Testing Week by Accesswire

GILD Financials

1-year income & revenue

Key terms

GILD Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

GILD Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Donald Trump might no longer own a majority of TMTG after a new public share offering.
Joe Raedle/Getty Images
Trump stock tanks after announcing massive share sale
1040 US Individual Income Tax Return Form
Nora Carol Photography/Moment RF/Getty Images
Three ways investors can minimize their tax payments
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Dow closes nearly 500 points lower on fears of potential Iranian attack on Israel
JPMorgan beat earnings expectations this Friday, unofficially kicking off the first quarter earnings season.
Win McNamee/Getty Images
Jamie Dimon says chance of a bad economy is ‘higher than other people think’